-
Hope for Chlamydia STI Vaccine After Promising Initial Results
- posted by: Lee Smith
- posted on: November 4, 2019
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials. The clinical studies were performed at Imperial College London and demonstrated the safety of the vaccine.
Read the rest of this post -
Gene Therapy for Rare Disorders
- posted by: Lee Smith
- posted on: July 24, 2019
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy. Unlike traditional treatments which seek to treat or manage diseases, or disorders by introducing agents outside the body, gene therapy uses the body itself to fight off such conditions.
Read the rest of this post -
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
- posted by: Lee Smith
- posted on: June 5, 2019
CEPI awards US$21 million to Themis Bioscience
Read the rest of this post -
Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate
- posted by: Lee Smith
- posted on: February 25, 2019
Chikungunya Vaccine receives FDA Fast Track Designation
Read the rest of this post -
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
- posted by: Lee Smith
- posted on: February 13, 2019
FluGen’s Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
Read the rest of this post -
Takeda Vaccine's Dengue Vaccine meets Primary Endpoints in its Phase III Efficacy Trial
- posted by: Lee Smith
- posted on: January 30, 2019
Takeda Vaccine's Dengue Vaccine meets its Primary Endpoints in Phase III Efficacy Trial.
Read the rest of this post -
Thoughts from the World Vaccine Congress, Washington 2018
- posted by: Lee Smith
- posted on: April 3, 2018
I'm currently attending the World Vaccine Congress 2018 in Washington to hear the latest musing from the sector's thought leaders and also find out about the latest technologies that are being used in the production of vaccines globally.
Read the rest of this post -
Themis Bioscience Enters into a $37.5m Agreement with CEPI to Develop a Lassa Fever and MERS-CoV Vaccine
- posted by: Lee Smith
- posted on: March 7, 2018
Themis Bioscience GmbH, an Austrian based vaccine company, has secured a $37.5m agreement with CEPI to create new vaccines for the infectious diseases Lassa Fever and MERS-CoV.
Read the rest of this post -
GRA Client, Themis Bioscience Start Phase II Chikungunya Clinical Study In Endemic Area
- posted by: Lee Smith
- posted on: August 8, 2017
Themis Bioscience begins testing of their Chikungunya vaccine in Puerto Rico phase II clinical study
Read the rest of this post